Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @ImageBoxLSPR
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @ImageBoxLSPR
-
Orgenesis sells Masthercell Global, its contract development and manufacturing organisation subsidiary. Will use $127 million to continue to grow its point-of-care
#celltherapy business and to further the development of its#ATMPs.https://tinyurl.com/whfbu7uHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Image Box LS PR proslijedio/la je Tweet
Akron's Ezequiel Zylberberg, along w/ co-authors Richard Harrison,
@Simon_H_Ellison &@BLLPHD, examines cost of goods associated w/ allogeneic CAR-T cell therapy manufacturing & delivery, modeling differentials across regions. A look at their findings:https://www.sciencedirect.com/science/article/pii/S1465324919300039 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Orgenesis appoints industry veteran Mario Philips, PolyNeuroS CEO, Archimed strategic partner and chair of board for Clean Biologics, to its board of directorshttps://tinyurl.com/u2fwxvx
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Orgenesis announces addition of University of California, Davis, to its Point of Care network; UC Davis Health to utilize Orgenesis’ Point of Care platform for the development, commercialization and supply of cell and gene therapy productshttps://tinyurl.com/s9uffwd
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Zelluna Immunotherapy, the biopharma company developing
#Tcell receptor#TCR guided adoptive#celltherapy products for treatment of multiple solid#cancers, today appoints Namir Hassan as chief executive officer (#CEO).https://tinyurl.com/yxyxfdj5Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Major
@medicine_maker cell and gene therapy supplement - Miguel Forte, Zelluna &@ISCTglobal on why TCRs have potential to expand on CAR-Ts & treat solid tumours http://tinyurl.com/rqcd7xyHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Major
@medicine_maker cell and gene therapy supplement - Vered Caplan, Orgenesis outlines cost reduction to#celltherapy if#hospitals & healthcare providers engaged in own process and development to treat their own#patients http://tinyurl.com/rqcd7xyHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Major
@medicine_maker cell and gene therapy supplement - Gabriel Festoc,@Polyplus_Transf outlines importance of GMP-grade reagents to the entire#celltherapy and#gene therapy sector. http://tinyurl.com/rqcd7xyHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Major
@medicine_maker cell and gene therapy supplement -@ISCTglobal 4-way interview including@BLLPHD on key considerations for the#celltherapy sector, including the talent gap and how it affects every element of the sector. https://tinyurl.com/rqcd7xyHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Major
@medicine_maker cell and gene therapy supplement - in-depth article on Ravi Nalliah, CEO,@TrakCel_ covering the past, present and future of TrakCel and the#celltherapy and#genetherapy sector. https://tinyurl.com/rqcd7xyHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Major highlight of the year:
@medicine_maker#celltherapy#genetherapy supplement is published, &@ImageBoxLSPR has secured key articles for@BLLPHD & 3@ISCTglobal leaders, Ravi Nalliah,@TrakCel_, Orgenesis, Zelluna &@Polyplus_Transf https://tinyurl.com/rqcd7xyHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Orgenesis Ranked 5th Fastest Growing Technology Company in Maryland and 208th in North America on 'Deloitte's 2019 Technology Fast 500'https://tinyurl.com/yx5u3zaj
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Zelluna Immunotherapy and Glycostem Therapeutics partner to develop allogeneic TCR-NK therapieshttps://tinyurl.com/tblohvh
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Orgenesis CEO Vered Caplan appears as a guest on “Israel Business Weekly” segment of Isreali i24 news network discussing how to transform the
#celltherapy &#GeneTherapy market & lower costs to deliver potentially life-saving#therapies to#patientshttps://tinyurl.com/yhhnuhdxHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Orgenesis Q3 2019 revenue increases 46% to record $9.1 million - strong year-over-year growth result of traction gaining from CDMO business & evolving POCare platformhttps://tinyurl.com/y4asjh43
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Immutep presents +ve interim PhII TACTI-002 trial data with Merck & Co (MSD), combining LAG-3 immunotherapy and Keytruda targeting lung cancer, running concurrently to other trials including with Pfizer, Merck & EOC & outlicenced trials with Novartis & GSK https://tinyurl.com/yxh8ad6v
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Image Box LS PR proslijedio/la je Tweet
ISCT forms cell and gene therapy sector-wide coalition to combat the rise of unproven commercial cell banking services
#Ethics#celltherapy@ISCTglobal@ISSCR@ASGCTherapy@ASTCT@sitcancer@TheEBMT@JACIE_EBMT@FACTunmc https://isctglobal.org/news/news.asp?id=474457 …pic.twitter.com/FzhKPpbSJX
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Orgenesis agrees co-development deal with Accellix to integrate proprietary optic system into Orgenesis’ Point of Care (“POCare”)
#celltherapy processing services and platformhttps://tinyurl.com/y55vwlx7Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Excellent to arrange interviews for major
#genetherapy report from@PwCHealth on the advanced capabilities needed to succeed after approval, for Bruce Levine,@BLLPHD,@ISCTglobal,@TrakCel_ and Vered Caplan, Orgenesis.https://tinyurl.com/yxsvcgugHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Great to get Miguel Forte, Zelluna Immunotherapy, and Marc Voigt,
@Immutep, covered in brilliant article reacting to UK Labour leader unveiling policy for the pharma sector by Madeleine Armstrong, for Vantage,@evaluatepharma.https://tinyurl.com/y6ngvw6jHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.